Incyte Corporation (INCY) News
Follow Incyte Corporation (INCY) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 47 public stories across 20 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Oppenheimer Sees Incyte Growth Path Beyond Jakafi Exclusivity Loss
Oppenheimer said Incyte is demonstrating a credible path to growth beyond Jakafi's 2029 loss of exclusivity.
EQUITY | Oct 30, 2026, 04:02 PM UTC
M
Incyte Q3 Revenue Rises 14% to $1.56 Billion; Guidance Trails Estimates
Incyte reported Q3 2026 revenue of $1.56 billion, up 14% year on year. Full-year revenue guidance was $5.26 billion at the midpoint, 11.3% below analysts’ estimates.
EQUITY | Oct 30, 2026, 03:59 PM UTC
M
Incyte Raises 2026 Revenue Forecast
Incyte raised its revenue forecast for 2026.
EARNINGS | Oct 29, 2026, 12:26 PM UTC
M
Incyte Raises 2026 Net Sales Forecast
EARNINGS | Oct 29, 2026, 12:17 PM UTC
M
Incyte eleva previsión de ventas netas para 2026 a entre $5,21 y $5,3 mil millones
EARNINGS | Oct 29, 2026, 12:16 PM UTC
M
Incyte Q3 Adjusted Loss Per Share Beats Estimates
EQUITY | Oct 29, 2026, 11:15 AM UTC
M
Incyte Raises 2026 Sales View to $5.21B-$5.3B
EARNINGS | Oct 29, 2026, 11:15 AM UTC
M
Incyte Swings to a Net Loss in Q3 2026
EARNINGS | Oct 29, 2026, 11:10 AM UTC
M
Incyte Reports Q3 Revenue of $1.56B vs. $1.46B Estimate
Incyte reported Q3 revenue of $1.56 billion, compared with the FactSet estimate of $1.46 billion.
EQUITY | Oct 29, 2026, 11:10 AM UTC
M
Incyte 3Q Jakafi/Jakafi XR Net Sales Rise 4% to $827M
Incyte reported third-quarter net sales of Jakafi and Jakafi XR of $827 million, up 4%.
EARNINGS | Oct 29, 2026, 11:09 AM UTC
M
Incyte Reports 71% Response Rate in Phase 1 Colorectal Cancer Trial
Incyte reported a 71% response rate for its INCA33890 combination in a Phase 1 colorectal cancer trial.
EQUITY | Oct 26, 2026, 01:46 PM UTC
L
Pharma sector doubles down on AI to slash costs, timelines
Pharmaceutical companies are increasingly turning to artificial intelligence to accelerate research and development, betting on new modeling tools and automated labs to improve efficiency across their pipelines.Industry
NEWS | Sep 29, 2026, 01:35 PM UTC
L
Incyte Is Maintained at Neutral by JP Morgan
Ratings actions from Benzinga
NEWS | Sep 28, 2026, 05:46 PM UTC
L
Weekly Recap: RBC $109 target and Mirum’s zilurgisertib milestone royalties
Incyte Corporation (NASDAQ:INCY) faces a mixed outlook as RBC keeps Sector Perform with a $109 target while the company readies U.S. launch of Atebrioz in October, gains a Rare Pediatric Disease priority review voucher,
NEWS | Sep 28, 2026, 11:05 AM UTC
L
Incyte Price Target Raised to $152.00/Share From $150.00 by HC Wainwright & Co.
Ratings actions from Benzinga
NEWS | Sep 28, 2026, 10:38 AM UTC
L
HC Wainwright & Co. maintains Buy rating on Incyte, $152 price target
HC Wainwright & Co. maintained their Buy rating on Incyte's stock with a price target of $152.00.The price target implies an upside of 22.7% from the Sep 25 close of $123.89.Key takeaways from the analyst noteStrong Valu
EQUITY | Sep 28, 2026, 10:28 AM UTC
L
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterot
REGULATION | Sep 25, 2026, 11:00 PM UTC
L
FDA Approves Atebrioz For Fibrodysplasia Ossificans Progressiva In Adults, Pediatric Patients
FDA
REGULATION | Sep 25, 2026, 09:48 PM UTC
L
INCY, MIRM Slip Into FDA’s Weekend Decision Date On Shared Rare-Disease Pill
Shares of Incyte (INCY) and Mirum Pharmaceuticals (MIRM) both eased on Friday after opening higher as traders waited for a weekend ruling from U.S. regulators on their shared rare-disease pill zilurgisertib.INCY opened u
REGULATION | Sep 25, 2026, 06:44 PM UTC
H
This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales
Zentalis Pharmaceuticals Inc. (NASDAQ: ZNTL ) received a bullish initiation from William Blair, which sees a potential blockbuster opportunity for the biotech company's lead cancer drug, azenosertib. William Blair analys
LIVE | Sep 16, 2026, 05:38 PM UTC
L
INCY: Late-stage pipeline progress and targeted launches position for strong post-2029 growth
Management outlined a strategy focused on advancing a robust late-stage pipeline, targeting $3—$4 billion in core business revenue and 15—20% CAGR through 2035. Key programs in oncology and rare diseases are progressing,
REGULATION | Sep 10, 2026, 02:37 PM UTC
L
INCY outlines dual strategy for core growth and late-stage pipeline
Management at INCY outlined a dual strategy: core business growth plus pipeline execution. The plan highlights five late-stage assets spanning hematology, oncology and immunology, with franchise-building in GI oncology a
EQUITY | Sep 09, 2026, 04:33 PM UTC
M
Incyte targets $3–4B by 2030 and $8–10B peak sales
Incyte management outlined a dual strategy of core business growth plus pipeline execution, targeting $3–4 billion by 2030 and $8–10 billion peak sales post-2029. Oncology, hematology and immunology assets are progressin
EQUITY | Sep 09, 2026, 04:06 PM UTC
L
Incyte announces agreement with CMS to improve medicine access
Incyte said it has agreed with CMS to improve medicine access.
EQUITY | Aug 31, 2026, 08:34 PM UTC
M
Incyte-CMS deal to supply Jakafi for state Medicaid
Incyte said it agreed with CMS to offer Jakafi and Jakafi XR to state Medicaid programs at aligned prices. It does not expect impact to 2026 guidance.
EQUITY | Aug 31, 2026, 08:32 PM UTC
L
Canaccord initiates Incyte at Buy, $152 target
Canaccord initiates Incyte (INCY) at Buy with a $152.00 price target; the alert supplies no additional catalyst or timing details.
EQUITY | Aug 20, 2026, 11:56 AM UTC
M
Incyte PT Raised to $155
Incyte price target increased
EQUITY | Aug 03, 2026, 10:56 AM UTC
H
Incyte Analysts Raise Their Forecasts After Upbeat Q2 Results
Incyte Corp. (NASDAQ: INCY ) on Tuesday reported better-than-expected second-quarter results and raised its full-year sales guidance. The biopharmaceutical company reported adjusted earnings of $3.09 per share, beating t
EARNINGS | Jul 29, 2026, 02:53 PM UTC
H
Top 3 Health Care Stocks That May Implode This Month
As of July 29, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a
EARNINGS | Jul 29, 2026, 12:45 PM UTC
H
Incyte Says It's No Longer A One-Drug Story
Incyte Corp. (NASDAQ: INCY ) reported better-than-expected second-quarter results on Tuesday and raised its full-year sales guidance after broad-based growth across its commercial portfolio, led by strong demand for Opze
EARNINGS | Jul 28, 2026, 07:10 PM UTC
H
among early movers from the earnings calendar this morning gainers IQV +10.2%, KNSA +9.4%, ITRI +7.9%, SHW +7.5%, PII +5.8%, CTS +5.0%, XPRO
among early movers from the earnings calendar this morning gainers IQV +10.2%, KNSA +9.4%, ITRI +7.9%, SHW +7.5%, PII +5.8%, CTS +5.0%, XPRO +3.8%, KO +3.8%, ABG +3.7%, AXTA +3.5%, OSK +3.3%, RGEN +2.6%, AWI +2.3%, ITW +
EARNINGS | Jul 28, 2026, 12:58 PM UTC
L
PRLD +20% in pre-mkt INCY - Prelude Therapeutics shares are higher in pre-mkt after Incyte discontinues further development of INCB160058. [
PRLD +20% in pre-mkt INCY - Prelude Therapeutics shares are higher in pre-mkt after Incyte discontinues further development of INCB160058. [Prelude Therapeutics' corresponding drug candidate is PRT12396, a mutant-selecti
EQUITY | Jul 28, 2026, 12:53 PM UTC
L
Incyte raises FY26 revenue view to $5.13B-$5.26B from $4.77B-$4.94B
Consensus $5.75B....
EQUITY | Jul 28, 2026, 11:10 AM UTC
H
Incyte reports Q2 EPS $3.09, consensus $2.15
Reports Q2 revenue...
EARNINGS | Jul 28, 2026, 11:08 AM UTC
H
INCY Incyte RESULTS: Q2, Q2 EPS $2.81, Q2 ADJ Operating Income $773.044M vs. EST $549.4M, Q2 REV $15M vs. EST $1.474B, Q2 ADJ EPS $3.09 vs.
INCY Incyte RESULTS: Q2, Q2 EPS $2.81, Q2 ADJ Operating Income $773.044M vs. EST $549.4M, Q2 REV $15M vs. EST $1.474B, Q2 ADJ EPS $3.09 vs. EST $2.1
EARNINGS | Jul 28, 2026, 11:01 AM UTC
H
Incyte Raises FY2026 Sales Guidance from $4.770B-$4.940B to $5.130B-$5.260B vs $5.712B Est
Incyte (NASDAQ: INCY ) raises FY2026 sales outlook from $4.770 billion-$4.940 billion to $5.130 billion-$5.260 billion vs $5.712 billion estimate.
EARNINGS | Jul 28, 2026, 11:00 AM UTC
L
Implied EPS movers for tomorrow AM: KO +/-2.8%, GLW +/-10.6%, BA +/-4.7%, SHW +/-6.1%, SPGI +/-4.5%, HLT +/-3.6%, PCAR +/-6.5%, RCL +/-7.3%,
Implied EPS movers for tomorrow AM: KO +/-2.8%, GLW +/-10.6%, BA +/-4.7%, SHW +/-6.1%, SPGI +/-4.5%, HLT +/-3.6%, PCAR +/-6.5%, RCL +/-7.3%, UPS +/-5.6%, AMT +/-5.9%, ITW +/-5.3%, CARR +/-5.5%, ECL +/-6.0%, CNC +/-8.1%,
EQUITY | Jul 27, 2026, 05:42 PM UTC
L
META NOW EBAY INCY - Final Trades on CNBC
META NOW EBAY INCY - Final Trades on CNBC
EQUITY | Jul 27, 2026, 04:59 PM UTC
L
INCY HALO Halozyme announces global collaboration and license agreement with Incyte to support the development of subcutaneous formulations
INCY HALO Halozyme announces global collaboration and license agreement with Incyte to support the development of subcutaneous formulations of inca033989 using its enhanze® technology Halozyme Therapeutics - to receive u
EQUITY | Jul 20, 2026, 12:03 PM UTC
H
INCY Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Suppor
INCY Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers Rapid oral presentat
GEOPOLITICS | Jul 17, 2026, 05:24 PM UTC
L
Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio
Acquisition adds VGA039, a novel investigational monoclonal antibody
EQUITY | Jul 06, 2026, 12:39 PM UTC
M
INCY Presents VGA039 Data
INCY Star Therapeutics is presenting complete data from a Phase 1/2 multidose study of VGA039 in Von Willebrand Disease at the ISTH 2026 Congress
EQUITY | Jun 26, 2026, 01:00 PM UTC
M
INCY Gets CHMP Nod
Incyte announces positive CHMP opinion for Opzelura cream for moderate atopic dermatitis treatment
EQUITY | Jun 26, 2026, 11:30 AM UTC
H
MU Price Target Raised
Needham raises Micron Technology price target from $500 to $1,550 and maintains Buy rating
EQUITY | Jun 22, 2026, 01:03 PM UTC
M
Banks Upgrade APA, COP, FANG
Roth Capital upgrades APA, COP, FANG to Buy, among other upgrades from various banks
EQUITY | Jun 22, 2026, 10:57 AM UTC
M
ROTH Upgrades APA, COP, FANG
ROTH upgrades APA, COP, and FANG to BUY, while BMO assigns MARKET PERFORM to INCY and JPM assigns OVERWEIGHT to VC
EQUITY | Jun 22, 2026, 09:50 AM UTC